I have two simple goals with this brief missive: Give well-deserved kudos to Adam Feuerstein for his call on

CV Therapeutics


that he recently added to the portfolio of Biotech Select, a premium service from TheStreet.com. And second, if you're interested in biotech stocks, you should subscribe to Biotech Select.

Adam added CV Therapeutics to the model portfolio of Biotech Select on Jan. 20, when the stock was trading at $10.75 a share. Shares of CVTX rose to $16.68 in intraday trading today on news that the company had received and rejected a $16-per-share takeover offer from Japanese drugmaker



Subscribers of Biotech Select who followed Feuerstein's buy suggestion gained more than 50% from this position in just five trading days!

Nice work, Adam.

Click here to take a free trial to Biotech Select

and receive all of Adam's commentary and stock recommendations.

Let's stay interactive.

Dave Morrow


David Morrow is editor-in-chief of TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, though he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. He appreciates your feedback;

click here

to send him an email.